Raymond James & Associates Trims Holdings in Atrion Co. (NASDAQ:ATRI)

Raymond James & Associates lessened its holdings in shares of Atrion Co. (NASDAQ:ATRI) by 4.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,754 shares of the medical instruments supplier’s stock after selling 82 shares during the period. Raymond James & Associates owned 0.09% of Atrion worth $1,303,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. PNC Financial Services Group Inc. bought a new position in Atrion in the fourth quarter valued at approximately $130,000. Quantamental Technologies LLC acquired a new stake in Atrion during the 4th quarter worth approximately $149,000. Waldron Private Wealth LLC acquired a new stake in Atrion during the 3rd quarter worth approximately $240,000. Wesbanco Bank Inc. acquired a new stake in Atrion during the 4th quarter worth approximately $259,000. Finally, WINTON GROUP Ltd acquired a new stake in Atrion during the 4th quarter worth approximately $346,000. Institutional investors own 61.74% of the company’s stock.

Several brokerages have weighed in on ATRI. BidaskClub cut Atrion from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. ValuEngine raised Atrion from a “hold” rating to a “buy” rating in a report on Monday, February 4th.

Shares of Atrion stock traded up $6.47 during trading on Friday, reaching $869.97. 4,201 shares of the company’s stock were exchanged, compared to its average volume of 6,550. The stock has a market capitalization of $1.61 billion, a P/E ratio of 47.31 and a beta of 0.44. Atrion Co. has a 1-year low of $560.65 and a 1-year high of $948.03.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were given a dividend of $1.35 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $5.40 dividend on an annualized basis and a yield of 0.62%.

TRADEMARK VIOLATION WARNING: “Raymond James & Associates Trims Holdings in Atrion Co. (NASDAQ:ATRI)” was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/atrion-co-atri-shares-sold-by-raymond-james-associates.html.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Recommended Story: Net Margin

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.